{
  "source": "PA-Notification-Copiktra.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1261-8\nProgram Prior Authorization/Notification\nMedication Copiktra® (duvelisib)\nP&T Approval Date 11/2018, 11/2019, 11/2020, 11/2021,5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nCopiktra (duvelisib) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ)\nindicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic\nleukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.1\nThe National Cancer Comprehensive Network (NCCN) also recommends the use of Copiktra\nfor the treatment of hepatosplenic T-cell lymphoma after two first-line therapy regimens and as\nsecond-line and subsequent therapy for relapsed/refractory breast implant-associated anaplastic\nlarge cell lymphoma (ALCL). The NCCN also recommends Copiktra as initial palliative intent\ntherapy or second-line and subsequent therapy for relapsed/refractory for certain peripheral T-\ncell lymphomas.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Copiktra will be approved based on the following criterion:\na. Member is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)\n1. Initial Authorization\na. Copiktra will be approved based on all of the following criteria:\n(1) Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic\nlymphoma (SLL)\n-AND-\n© 2025 UnitedHeal",
    "itial Authorization\na. Copiktra will be approved based on all of the following criteria:\n(1) Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic\nlymphoma (SLL)\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\n(2) Disease is relapsed or refractory\n-AND-\n(3) History of failure, contraindication, or intolerance to at least two prior therapies\nfor CLL/SLL. Examples include, but not limited to, regimens consisting of:\nLeukeran (chlorambucil), Gazyva (obinutuzumab), Arzerra (ofatumumab),\nBendeka (bendamustine), Imbruvica (ibrutinib), Calquence (acalabrutinib),\nVenclexta (venetoclax), etc.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Copiktra will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Copiktra\ntherapy\nAuthorization will be issued for 12 months.\nC. T-cell Lymphomas\n1. Initial Authorization\na. Copiktra will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Diagnosis of Hepatosplenic T-cell lymphoma\n-AND-\n(b) Disease is relapsed or refractory\n-AND-\n(c) History of failure, contraindication, or intolerance to at least two prior\nsystemic therapies\n-OR-\n(2) All of the following:\n(a) Diagnosis of Breast implant-associated anaplastic large cell lymphoma\n-AND-\n(b) Disease is relapsed or refractory\n© 2025 UnitedHealthcare Services Inc.\n2\n-AND-\n(c) Used as second-line and subsequent therapy\n-OR-\n(3) Both of the following:\n(a) Diagnosis of Peripheral T-cell lymphoma\n-AND-\n(b) One of the following:\ni. Used as initial palliative intent therapy\nii. Used as second-line and subsequent therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Copiktra will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Copiktra\ntherapy\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The Nationa",
    "rogressive disease while on Copiktra\ntherapy\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services Inc.\n3\n4. References:\n1. Copiktra [package insert]. Las Vegas, NV: Secura Bio; July 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed on March 31, 2025.\nProgram Prior Authorization/Notification – Copiktra (duvelisib)\nChange Control\n11/2018 New program.\n11/2019 Annual review. Added coverage for additional B cell lymphomas.\nAdded NCCN recommended regimens criteria. Updated background\nand references.\n11/2020 Annual review. Added additional first line NCCN treatment examples.\nNo change to clinical criteria. Updated references.\n11/2021 Annual review with no change to clinical criteria. Updated reference.\n5/2022 Annual review. Removed coverage for gastric and nongastric MALT\nlymphomas, splenic marginal zone lymphoma, and nodal marginal zone\nlymphoma. Added coverage for T-cell lymphomas. Updated\nbackground and references.\n5/2023 Annual review. Added state mandate. Updated the background with no\nchanges to clinical criteria. Update",
    "al zone\nlymphoma. Added coverage for T-cell lymphomas. Updated\nbackground and references.\n5/2023 Annual review. Added state mandate. Updated the background with no\nchanges to clinical criteria. Updated references.\n5/2024 Annual review with no change to clinical criteria. Updated reference.\n5/2025 Annual review. Updated criteria for peripheral T-cell Lymphoma based\non NCCN guidance. Updated references and background.\n© 2025 UnitedHealthcare Services Inc.\n4"
  ]
}